Direct-Acting Antiviral Drugs and Occurrence of Hepatocellular Carcinoma: Unjust or Oppressed.
Sahar M HassanyWesam HassanHany Abo-AlamMarwa KhalafAmany M NafehEman Nasr-EldinEhab F MostafaPublished in: Infection and drug resistance (2020)
Treatment of HCV-related LC patients with sofosbuvir and daclatasvir with or without ribavirin for 3 or 6 months showed high SVR and significant improvement in CP score, but still at risk of HCC even if treated and should be followed up regularly according to screening programs with special meticulous attention to those with non-SVR.